Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Reports Third Quarter 2016 Financial Results and Announces Completion of Subject Visits for Twirla® Phase 3 SECURE Clinical Trial
Top-Line Data Expected in Early January 2017; Resubmission Planned for First Half 2017  Cash Expected to Fund Operations Through the End of 2017 PRINCETON, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company, today...
Toggle Summary Agile Therapeutics Reports Second Quarter 2016 Financial Results
Twirla® Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017; Cash Expected to Fund Operations Through the End of 2017...
Toggle Summary Agile Therapeutics Appoints Seth H. Z. Fischer to its Board of Directors
Industry Veteran Brings Significant Management and Commercial Experience...
Toggle Summary Agile Therapeutics Announces Plans to Advance Contraceptive Pipeline
Preparations Underway for Phase 2 Clinical Trial of Novel Twirla® Line Extension...
Toggle Summary Agile Therapeutics Strengthens Executive Leadership Team with New Chief Commercial Officer
Appoints Former Senior J&J Executive responsible for leading launch of ORTHO EVRA®...
Toggle Summary Agile Therapeutics to Present at the Cantor Fitzgerald's 2nd Annual Healthcare Conference
Presentation Scheduled on Wednesday, July 13th, 2016 at 1:00 PM ET ...
Toggle Summary Agile Therapeutics Announces Issuance of Patent for Progestin Patch Designs
Intellectual Property Portfolio Broadened for Its Proprietary Transdermal Delivery System...
Toggle Summary Agile Therapeutics to Present at the William Blair & Company's 36th Annual Growth Stock Conference
Presentation Scheduled on Tuesday, June 14th, 2016 at 2:50 PM Central Time...
Toggle Summary Agile Therapeutics to Present at the Jefferies 2016 Healthcare Conference
Presentation Scheduled on Friday, June 10th, 2016 at 10:30 AM Eastern Time...
Toggle Summary Agile Therapeutics Reports First Quarter 2016 Financial Results
Cash Expected to Fund Operations through the End of 2017 Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017 PRINCETON, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical...
Shadow